LFG
TGTX icon

Larson Financial Group’s TG Therapeutics TGTX Stock Holding History

Larson Financial Group’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-300
Closed -$300 – 3790
2025
Q4 		$300 Hold
300
– – ﹤0.01% 3213
2025
Q3 		$1.94K Buy
+300
New +$9.88K ﹤0.01% 2721

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Larson Financial Group's TGTX Position: Q2 2026 in Review

Larson Financial Group reduced its TG Therapeutics (TGTX) stake by 2.6% in Q2 2026, selling an estimated $8.1K and leaving 7,292 shares worth $401K. The position accounts for 0.01% of the portfolio, ranked #620.

Larson Financial Group first reported a position in TGTX in Q4 2024 and has held it in 7 quarters since. 430 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Larson Financial Group held 7,292 shares of TG Therapeutics worth $401K as of Q2 2026.
  • Larson Financial Group sold 198 TG Therapeutics shares in Q2 2026, an estimated $8.1K.
  • TG Therapeutics made up 0.01% of Larson Financial Group's portfolio in Q2 2026, its #620 holding.
  • Larson Financial Group first reported a position in TG Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 430 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.